Current and future therapeutic approaches for the treatment of small cell lung cancer

Expert Review of Anticancer Therapy

Volumn 18, Issue 5, 2018, Pages 473-486

  Rossi, Antonio ^a   Tay, Rebecca ^b   Chiramel, Jaseela ^b   Prelaj, Arsela ^b,c   Califano, Raffaele ^b,d,e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Durvalumab; immunotherapy; ipilimumab; nivolumab; pembrolizumab; rovalpituzumab tesirine; SCLC; second line; targeted therapy; tremelimumab

Indexed keywords

ALPHA INTERFERON; AMRUBICIN; BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; LORVOTUZUMAB MERTANSINE; MARIMASTAT; OBATOCLAX; PACLITAXEL; PEMETREXED; PICOPLATIN; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VINCRISTINE; VINORELBINE TARTRATE; VISMODEGIB; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKULL IRRADIATION; SMALL CELL LUNG CANCER; THROMBOSIS; UNSPECIFIED SIDE EFFECT; DRUG DESIGN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SMALL CELL LUNG CARCINOMA;

EID: 85045296183     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2018.1453361     Document Type: Review

References (103)

1. van Meerbeeck JP, Fennell DA, De Ruysscher DK., Small-cell lung cancer. Lancet. 2011;378:1741–1755.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2006;24:4539–4544.
3. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12:1096–1104.
4. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015;10:1243–1260.
5. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinico-pathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–1197.
6. Testa JR, Liu Z, Feder M, et al. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet. 1997;95:20–32.
7. Fruh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–vi105.
8. Stahel RA, Ginsberg RJ, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5:119–126.
9. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2:1067–1077.
10. Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005;129:977–983.
11. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–1624.
12. Livingston RB, Moore TN, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med. 1978;88:194–199.
13. Goldhirsch A, Joss R, Cavalli F, et al. Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treat Rev. 1982;9:85–90.
14. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3:1471–1477.
15. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20:4665–4672.
16. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794–1801.
17. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855–861.
18. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692–1698.
19. Warde P, Payne D., Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–895.
20. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11:336–344.
21. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer. 2002;38:279–291.
22. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116–1125.
23. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–3060.
24. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.
25. Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–2535.
26. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.
27. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17:2092–2099.
28. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42.
29. Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive stage small-cell lung cancer - Authors’ reply. Lancet. 2015;385:1292–1293.
30. Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 2017;108:150–153.
31. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer. 2009;115:842–850.
32. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10:467–474.
33. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663–671.
34. Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33:4106–4111.
35. Zhou H, Zeng C, Wei Y, et al. Duration of chemotherapy for small cell lung cancer: a meta-analysis. PLoS One. 2013;8:e73805.
36. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010;70:119–128.
37. Roviello G, Zanotti L, Cappelletti MR, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016;17:334–340.
38. Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol. 2015;26:908–914.
39. Dr S, Pm T, Dm W, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215–2222.
40. Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35:1281–1287.
41. Ready NE, Pang HH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015;33:1660–1665.
42. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20. J Clin Oncol. 2007;25:4278–4284.
43. Sanborn RE, Patel JD, Masters GA, et al. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer. 2017;123:303–311.
44. Sharma N, Pennell N, Nickolich M, et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs. 2014;32:362–368.
45. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007;25:3945–3951.
46. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101:1049–1057.
47. Langer CJ, Albert I, Ross HJ, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85:420–428.
48. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002;20:4434–4439.
49. Gladkov O, Ramlau R, Serwatowski P, et al. Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Anticancer Drugs. 2015;26:1061–1068.
50. Ardizzoni A, Tiseo M, Boni L, et al. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur J Cancer. 2014;50:2211–2218.
51. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second line chemotherapy in sensitive and refractory small cell lung cancer. J Thorac Oncol. 2012;7:866–872.
52. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer. 1987;23:1697–1699.
53. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096.
54. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667.
55. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447.
56. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092.
57. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401–5406.
58. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29:287–293.
59. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012–4019.
60. Horita N, Yamamoto M, Sato T, et al. Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Sci Rep. 2016;6:18999.
61. Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1147–1157.
62. Genestreti G, Tiseo M, Kenmotsu H, et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin Lung Cancer. 2015;16:e223–e228.
63. Rossi A, Sacco PC, Sgambato A, et al. Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert Opin Pharmacother. 2016;17:969–976.
64. Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014;9:559–562.
65. Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer. 2014;86:237–240.
66. Zhou ZT, Zhou FX, Wei Q, et al. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68:1027–1032.
67. Lu S, Li L, Luo Y, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10:206–211.
68. Socinski MA, Kaye FJ, Spigel DR, et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clin Lung Cancer. 2017;18:68–76.
69. Belani CP, Dahlberg SE, Rudin CM, et al. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016;122:2371–2378.
70. Glisson B, Besse B, Dols MC, et al. A Randomized, placebo-controlled, phase 1b/2 study of rilotumumab or ganitumab in combination with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer. Clin Lung Cancer. 2017;18:615–625.
71. Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35:1506–1514.
72. Spigel DR, Waterhouse DM, Lane S, et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer. 2013;14:356–363.
73. Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol. 2016;77:713–722.
74. Jalal S, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010;5:2008–2011.
75. Mountzios G, Emmanouilidis C, Vardakis N, et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer. 2012;77:146–150.
76. Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014;32:2463–2470.
77. Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013;79:137–142.
78. Koinis F, Agelaki S, Karavassilis V, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer. 2017;117:8–14.
79. Han JY, Kim HY, Lim KY, et al. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108–112.
80. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
81. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83.
82. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740–3748.
83. Gadgeel SM, Ventimiglia J, Kalemkerian GP, et al. Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts). J Clin Oncol. 2017;35(Suppl.):8504. (abstract).
84. Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35:3823–3829.
85. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–895.
86. Hellmann M, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 2017;35(Suppl.):8503. (abstract).
87. Antonia SJ, Callahan MK, Awad MM, et al. Impact of tumor mutation burden on the efficacy of nivolumab or nivolumab plus ipilimumab in small cell lung cancer: an exploratory analysis of CheckMate 032. J Thorac Oncol. 2017;12:OA 07. 03a (abstract).
88. Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death‐ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426–430.
89. Komiya T, Madan R. PD‐L1 expression in small cell lung cancer. Eur J Cancer. 2015;51:1853–1855.
90. Inamura K, Yokouchi Y, Kobayashi M, et al. Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor. Cancer Med. 2017;6:2347–2356.
91. Schultheis AM, Scheel AH, Ozretic L, et al. PD‐L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51:421–426.
92. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.
93. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.
94. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol. 2003;31:446–454.
95. Woodhouse BC, Dianova II, Parsons JL, et al. Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks. DNA Repair (Amst). 2008;7:932–940.
96. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.
97. Wainberg ZA, Rafii S, Ramanathan RK, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. J Clin Oncol. 2014;32(Suppl. 15):7522. (abstract).
98. Stewart CA, Tong P, Cardnell R, et al. SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC). Cancer Res. 2016;76(Suppl. 14):3870. (abstract).
99. Byers LA, Krug L, Waqar S, et al. Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: results from a phase II trial. J Thorac Oncol. 2017;12:S406–S407. (abstract MA11.07).
100. Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol. 2014;32:57–59.
101. Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.
102. Mollaoglu G, Guthrie MR, Böhm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270–285.
103. Pallis AG, Shepherd FA, Lacombe D, et al. Treatment of small-cell lung cancer in elderly patients. Cancer. 2010;116:1192–1200.